STAT Plus: Watch: Top Biogen scientist explains why he’s confident in company’s drug for Alzheimer’s
Does the Alzheimer’s drug aducanumab work?
That was the central issue during an interview of Biogen’s head of research and development and chief medical officer, Dr. Al Sandrock, at the STAT Summit in Cambridge, Mass., late last month. Sandrock’s answer, in short, was undoubtedly yes.
Continue to STAT Plus to read the full story…
